Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $26M (down 63.5% year over year) with net income of −$101M.
Q3 2026 key financials · XBRL
- Revenue
- $26M
- −63.5% YoY · +8967.6% QoQ
- Net income
- −$101M
- −192.5% YoY · +20.4% QoQ
- Operating margin
- -401.8%
Source: XBRL data from the Viridian Therapeutics, Inc.\DE (VRDN) Q3 2026 10-Q on SEC EDGAR. USD.
Viridian Therapeutics, Inc.\DE Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $24.7M, versus $70.0M license revenue in Q3 2025, driven by new veligrotug sales
- Net loss $101.2M vs $34.6M YoY, with cost of revenues $1.5M and SG&A $57.6M
- TED R&D largest at $23.9M, down $31.3M YoY; other research programs increased $5.9M to $7.2M
- Cash, equivalents and marketable securities $955.2M; operating cash use $317.8M through nine months
- Outlook: elegrobart BLA expected Q1 2027; macroeconomic uncertainty, tariffs, inflation and supply-chain risks
Risk Factors
- Newly emphasized regulatory risk: BIOSECURE Act enacted December 2025, potentially restricting WuXi services and U.S. government contracting
- Most material update: FDA disruption risk from federal shutdowns and workforce reductions, threatening BLA reviews and inspections
- Operational risk: Single-sourced manufacturing with WuXi for veligrotug and product candidates, exposing supply continuity
- Competitive risk: More than 20 FcRn indications in development, increasing potential competition for the pipeline
- Financial risk: $250.0 million 1.75% convertible senior notes due 2032, requiring future cash servicing or refinancing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Viridian Therapeutics, Inc.\DE quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.